DE69314041T2 - Cyanoguanidine als kaliumkanalblocker - Google Patents

Cyanoguanidine als kaliumkanalblocker

Info

Publication number
DE69314041T2
DE69314041T2 DE69314041T DE69314041T DE69314041T2 DE 69314041 T2 DE69314041 T2 DE 69314041T2 DE 69314041 T DE69314041 T DE 69314041T DE 69314041 T DE69314041 T DE 69314041T DE 69314041 T2 DE69314041 T2 DE 69314041T2
Authority
DE
Germany
Prior art keywords
cyano
pyridyl
product
guanidine
meoh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69314041T
Other languages
German (de)
English (en)
Other versions
DE69314041D1 (de
Inventor
Jackson Hester
Stephen Humphrey
James Ludens
Kaushik Meisheri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of DE69314041D1 publication Critical patent/DE69314041D1/de
Application granted granted Critical
Publication of DE69314041T2 publication Critical patent/DE69314041T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69314041T 1992-08-13 1993-07-21 Cyanoguanidine als kaliumkanalblocker Expired - Fee Related DE69314041T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92979592A 1992-08-13 1992-08-13
PCT/US1993/006752 WO1994004500A1 (en) 1992-08-13 1993-07-21 Cyanoguanidines as potassium channel blockers

Publications (2)

Publication Number Publication Date
DE69314041D1 DE69314041D1 (de) 1997-10-23
DE69314041T2 true DE69314041T2 (de) 1998-02-05

Family

ID=25458467

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69314041T Expired - Fee Related DE69314041T2 (de) 1992-08-13 1993-07-21 Cyanoguanidine als kaliumkanalblocker

Country Status (16)

Country Link
US (1) US5567722A (enExample)
EP (1) EP0655057B1 (enExample)
JP (1) JPH08500111A (enExample)
CN (1) CN1039997C (enExample)
AT (1) ATE158279T1 (enExample)
AU (2) AU4530693A (enExample)
DE (1) DE69314041T2 (enExample)
DK (1) DK0655057T3 (enExample)
ES (1) ES2107049T3 (enExample)
GR (1) GR3025640T3 (enExample)
IL (1) IL106641A (enExample)
MX (1) MX9304882A (enExample)
MY (1) MY110826A (enExample)
TW (1) TW223017B (enExample)
WO (2) WO1994004499A1 (enExample)
ZA (1) ZA935619B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2116726T3 (es) * 1994-01-28 1998-07-16 Upjohn Co Cianoguanidinas utilizadas como bloqueadores del canal k.
AUPN193095A0 (en) * 1995-03-24 1995-04-27 Polychip Pharmaceuticals Pty Ltd Potassium ion channel blockers
WO1998006398A1 (en) * 1996-08-15 1998-02-19 Smithkline Beecham Corporation Il-8 receptor antagonists
AR008290A1 (es) 1996-08-15 1999-12-29 Smithkline Beecham Corp Nuevos compuestos que contienen guanidina utiles como antagonistas de los receptores de il-8, composiciones farmaceuticas que los contienenprocedimiento para la preparacion de dichos compuestos y procedimiento para la preparacion de intermediarios.
GB9711124D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711127D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711126D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Cyanoamidines
GB9711125D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711123D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
WO2007022964A2 (de) 2005-08-24 2007-03-01 Abbott Gmbh & Co. Kg Hetaryl substituierte guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
CN113683535B (zh) * 2020-05-18 2022-08-30 中国药科大学 含氰胍结构的化合物及其制备方法与用途
CN112042664B (zh) * 2020-09-18 2022-06-10 广州古神生物科技有限公司 防霉抗菌剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1489879A (en) * 1974-12-20 1977-10-26 Leo Pharm Prod Ltd N'-cyano-n'-3-pyridylguanidines
US4287346A (en) * 1979-02-16 1981-09-01 Eisai Co., Ltd. Cyanoguanidine derivatives
JPH01166119A (ja) * 1987-12-23 1989-06-30 Hitachi Ltd データ入力装置の制御方式
NZ229828A (en) * 1988-08-09 1992-03-26 Squibb & Sons Inc Aryl cyanoguanidine derivatives and pharmaceutical compositions
AU623217B2 (en) * 1989-02-03 1992-05-07 Eli Lilly And Company (-)-n"-cyano-n-3-pyridyl-n'-1,2,2-trimethyl- propylguanidine, a process for preparing the compound, and use of the compound as a medicament
US5006523A (en) * 1989-10-26 1991-04-09 E. R. Squibb & Sons, Inc. Antiarrhythmic agents: aryl cyanoguanidine potassium channel blockers

Also Published As

Publication number Publication date
JPH08500111A (ja) 1996-01-09
ZA935619B (en) 1995-02-03
EP0655057A1 (en) 1995-05-31
TW223017B (enExample) 1994-05-01
GR3025640T3 (en) 1998-03-31
DE69314041D1 (de) 1997-10-23
AU4683193A (en) 1994-03-15
CN1090575A (zh) 1994-08-10
DK0655057T3 (da) 1998-04-14
IL106641A (en) 2001-01-11
WO1994004500A1 (en) 1994-03-03
ATE158279T1 (de) 1997-10-15
AU4530693A (en) 1994-03-15
ES2107049T3 (es) 1997-11-16
IL106641A0 (en) 1993-12-08
MX9304882A (es) 1994-07-29
CN1039997C (zh) 1998-09-30
US5567722A (en) 1996-10-22
WO1994004499A1 (en) 1994-03-03
MY110826A (en) 1999-05-31
EP0655057B1 (en) 1997-09-17

Similar Documents

Publication Publication Date Title
DE69304076T2 (de) N-cyano-n'-pyridylguanidine als serotoninantagonisten
DE2557438C2 (enExample)
DE69132961T2 (de) Styrylsubstituierte heteroarylverbindungen, welche egf-rezeptor-tyrosinkinase inhibieren
DE69314041T2 (de) Cyanoguanidine als kaliumkanalblocker
EP0313974A1 (de) N-substituierte Derivate von 1-Desoxynojirimycin und 1-Desoxymannonojirimycin, Verfahren zu deren Herstellung und deren Verwendung in Arzneimitteln
DD216929A5 (de) Verfahren zur herstellung von thiazolidinderivaten
EP0688771B1 (de) Verwendung von Lactamverbindungen als pharmazeutische Wirkstoffe
DE69502584T2 (de) Cyanoguanidine als k-kanal-blocker
DE2847792C2 (enExample)
DE2524277C2 (enExample)
EP0104423B1 (de) 2-Nitro-1,1-ethendiamine, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
DE69817810T2 (de) Cyanoguanidine als zellproliferation inhibitoren
EP1317430B1 (de) (2-azabicyclo [2.2.1]hept-7-yl)methanol-derivate als nikotinische acetylcholinrezeptor agonisten
DE3217769A1 (de) Mitomycon-analoge verbindungen
EP0435902B1 (de) 2-hydroxy-3-phenoxy-propyl-substituierte piperazine, ihre herstellung und verwendung
DE2355262C3 (de) 1-Piperidinsulfonylharnstoffe, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate
DE69120221T2 (de) Pyrimidin-verbindung und ihr pharmazeutisch annehmbares salz
DE69323633T2 (de) Pyrimidine-cyanoguanidine als kaliumkanalblocker
DE2419198A1 (de) Pyridincarboxamidsulfonylharnstoffe als hypoglykaemische mittel
DE2733698A1 (de) 1-niederalkyl-4,5-dihydro-5-phenyl- 2-niederalkoxycarbonylaminoimidazole und deren im phenylrest substituierte derivate
DE1670844C3 (de) Arylsulfonylharnstoffe und Verfahren zu ihrer Herstellung
DE2628642C2 (de) In 2-Stellung substituierte 1,3-Diaza-fünfringkohlenstoffverbindungen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
DE3107599C2 (de) N-Cyan-N'-methyl-N"-{2-[(5-methylthio-imidazol-4-yl)-methylthio]-äthyl}-guanidin, Verfahren zu seiner Herstellung und diese Verbindung enthaltende Arzneimittel
DE3233380A1 (de) Substituierte pyridyl-cyanoguanidinverbindungen
DE2629133C2 (de) 5"-Amino-3',5"-didesoxyribostamycin, Verfahren zu dessen Herstellung sowie antimikrobielle Zubereitungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee